DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma
[Technical Report, Annual Report]
The University of Texas MD Anderson Cancer Center
Pagination or Media Count:
A recent breakthrough in treating melanoma patients is the use of immune checkpoint therapy ICT. Unfortunately, the majority of patients do not respond to ICT. Complicating matters, is that as cancer develops, it can re-program immune cells to work in favor of tumor growth. One such population of cells are myeloid-derived suppressor cells MDSCs. MDSCs dampen the immune system from recognizing cancer and decrease ICT treatment response. Preliminary data suggests that the enzyme myeloperoxidase is overexpressed in MDSCs. We hypothesize that by limiting the function of myeloperoxidase, we limit the effects of MDSCs to enable successful ICT response in melanoma.
[A, Approved For Public Release]